These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20008549)

  • 1. A strategy for risk management of drug-induced phospholipidosis.
    Chatman LA; Morton D; Johnson TO; Anway SD
    Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assays and biomarkers for drug-induced phospholipidosis.
    Monteith DK; Morgan RE; Halstead B
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
    Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
    Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
    Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
    Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
    van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
    Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
    Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
    Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
    Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
    Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
    Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
    Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced phospholipidosis.
    Anderson N; Borlak J
    FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro Screen.
    Fusani L; Brown M; Chen H; Ahlberg E; Noeske T
    Mol Pharm; 2017 Dec; 14(12):4346-4352. PubMed ID: 29077420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
    Tengstrand EA; Miwa GT; Hsieh FY
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
    Sawada H; Takami K; Asahi S
    Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
    Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
    Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular responses associated with dibucaine-induced phospholipidosis.
    Peropadre A; Fernández Freire P; Herrero O; Pérez Martín JM; Hazen MJ
    Chem Res Toxicol; 2011 Feb; 24(2):185-92. PubMed ID: 21261262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
    Miyamoto S; Matsumoto A; Mori I; Horinouchi A
    Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
    Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
    J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
    Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
    Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
    McCloud CM; Beard TL; Kacew S; Reasor MJ
    Exp Mol Pathol; 1995 Feb; 62(1):12-21. PubMed ID: 7556587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS.
    Hasegawa M; Takenaka S; Kuwamura M; Yamate J; Tsuyama S
    Exp Toxicol Pathol; 2007 Oct; 59(2):115-20. PubMed ID: 17719757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
    Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
    Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.